New cell therapy HN2301 enters human trials for autoimmune diseases
Disease control
Recruiting now
This early-stage study tests a new therapy, HN2301, in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the treatment helps control the disease by measuring immune…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC